$0.00
Shopping Cart
Facebook-f Instagram
Donate

Clinical Trial Record

Return to Clinical Trials

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

2020-09-02

2025-09

2025-09

10

Study Overview

Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver

This study will look at whether it is practical and safe to give Lutathera directly into an artery of the liver (hepatic intraarterial infusion). The researchers will compare the effects of hepatic intraarterial infusion in the liver with the effects of the standard approach (intravenous infusion in the arm). The researchers will also determine whether Lutathera is effective against participants' cancer.

N/A

  • Neuroendocrine Tumors
  • Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors
  • DRUG: 177Lu-DOTATATE
  • 20-232

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2020-09-03  

N/A  

2024-05-01  

2020-09-03  

N/A  

2024-05-02  

2020-09-10  

N/A  

2024-05  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Na

Interventional Model:
Single Group

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: PRRT with 177Lu-DOTATATE

Patients will undergo a routine 68Ga-DOTATATE PET/CT. Patients with sufficient tumor uptake will be offered therapy with 177Lu-DOTATATE. The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intrav

DRUG: 177Lu-DOTATATE

  • The treatment regimen will consist of four administrations of 177Lu-DOTATATE-two intra-arterial followed by two intravenous, two months apart (+/- 2 weeks), with renal protective amino acid solution co-administration. The activity per cycle will be fixed
Primary Outcome MeasuresMeasure DescriptionTime Frame
number of patients who successfully complete 2 IA injectionsFeasibility will be defined as at least 7 or more patients out of 10 patients who successfully complete 2 IA injections.2 years
Objective responseclassified according to RECIST 1.1 criteria1 year
Secondary Outcome MeasuresMeasure DescriptionTime Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • Subjects affected by histologically proven, somatostatin-receptor positive, progressive, nonresectable, liver-dominant metastatic GEP, bronchial or unknown primary tumors, G1, G2 and G3, according to the new WHO classification of 2017.

    • 1. Ability to understand and willingness to sign a written informed consent document 2. Aged 18 years or older 3. Histologically proven or cytologically confirmed, non-resectable,GEP, bronchial or unknown primary NETs with liver-dominant disease with or without prior treatment with embolization 4. Measurable disease as defined by RECIST 1.1 with at least one dimension ≥ 1.0 cm 5. GEP or unknown primary NET of grade 1, 2 and 3 according to WHO 2017, typical or atypical lung carcinoid according to the Travis classification of 2004 6. Progression of disease defined by one of the following occurring within 6 months of study entry:
    1. At least a 20% increase in radiologically or clinically measurable disease; 2. Appearance of any new lesion; 3. Symptomatic disease (including worsening hormonal symptoms or symptoms related to tumor burden); 7. Overexpression of somatostatin receptors of the target lesions at 68Ga-DOTATATE PET/CT with SUV of lesions greater than normal liver at least in 1 metastasis. 8. ECOG performance status 0 or 1 (Karnofsky ≥ 70%). 9. Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. 10. Previous local therapy (e.g., chemoembolization or bland embolization) is allowed if completed >6 weeks prior to study entry. For such patients, there must be either progression of measurable disease documented within the treatment field, or measurable progressive disease outside the treatment field prior to study entry. 11. Previous oral chemotherapy, biotherapy (such as Interferons or Everolimus) and/or investigational agents are allowed if completed >4 weeks prior to study entry For patients who received systemic therapy prior to study entry, there must be documented progression of measurable disease since receiving systemic therapy prior to study entry. 12. Patients must not be candidate for potentially curative surgery. Prior surgery is allowed no less than 6 weeks prior to study entry. Note: Patients who have disease that is amendable to resection but who are not a surgical candidate for other medical reasons would be permitted.
    Exclusion Criteria:
    1. Women who are pregnant or breastfeeding 2. History of allergic reactions attributed to compounds of similar chemical or biologic composition to 177Lu-DOTATATE as assessed from medical records. 3. Life expectancy < 6 months as assessed by the treating physician. 4. Over 80% liver involvement by tumor per the judgement of the radiologist 5. Poorly differentiated neuroendocrine neoplasms (Neuroendocrine Carcinoma), small and large cell type; Mixed Neuroendocrine-Nonneuroendocrine Neoplasm (MiNEN). 6. Presence of somatostatin receptor negative lesions. 7. Prior treatment with other radiolabeled somatostatin analogs. 8. Prior systemic chemotherapy, except oral chemotherapy with capecitabine + temozolomide 9. Contraindication to angiography/embolization including:
    1. Patients cannot receive contrast 2. Severe allergic reaction to contrast despite premedication. Patients in who IV contrast is contraindicated are recommended to have MRI abdomen and noncontrast chest CT scan. 3. Poor renal function not on dialysis 4. Other, based on judgment of the investigator 10. Main portal vein tumor thrombus. 11. Deteriorated renal function:
    1. Serum creatinine >1.7 mg/dL OR 2. EGFR <30 ml/min 12. Deteriorated bone marrow function:
    1. Hb <8.0 g/dL; 2. WBC <3000/mm3; 3. ANC<1500/mm3; 4. Platelets <75.000/mm3 13. Deteriorated liver function:
    1. INR > 2.0 for patients that are not on Coumadin or Xarelto 2. PTT > 2x ULN 3. Total bilirubin >3 mg/dl 4. Serum albumin <3.0 g/dL unless prothrombin time is within the normal range. 14. Clinically relevant toxicities from prior therapies that have not resolved to grade 1 or grade 0 15. Previous liver radioembolization with 90Y-microspheres. 16. Known brain metastases and/or carcinomatous meningitis, unless these metastases have been treated and stabilized. 17. Uncontrolled diabetes mellitus 18. Inability to interrupt short-acting Octreotide for 24 h before and 24 h after the administration of 177Lu-DOTATATE; inability to have an interval between Octreotide LAR and 177Lu-DOTATATE of ≥4 weeks 19. Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 20. Prior external beam radiation therapy involving >25% of the bone marrow. 21. Unmanageable urinary incontinence rendering the administration of 177Lu-DOTATATE unsafe 22. Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and with no evidence of recurrence.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

    • PRINCIPAL_INVESTIGATOR: Lisa Bodei, MD, PhD, Memorial Sloan Kettering Cancer Center

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available

    Treat yourself

    Let Us Take Care Of You

    BOOK AN APPOINTMENT ⟶
    footer logo

    About

    Events

    Fundraising

    Contact Us

    Facebook-f Instagram

    NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.

    The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.

    Copyright © 2024 – National Pancreatic Cancer Foundation | All Rights Reserved

    Make-A-Will Month

    Snag 6508be92
    Learn More
    Donate Now Online
    Other Ways to Donate